Vaccines for both pandemic and seasonal influenza, as well as other infectious diseases, based on proprietary Toll-like Receptor (TLR) technology platform. Clinical stage.
Cranbury, NJ
Cranbury, NJ
Total raised: $6.6M
Investors 1
| Date | Name | Website |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.10.2014 | - | $6M | - |
| 26.07.2007 | Grant | $597K | - |
Mentions in press and media 8
| Date | Title | Description |
| 29.09.2015 | VaxInnate keeps slowly raising capital for seasonal flu vaccine | The company launched a Phase 2 study of its VAX2012Q seasonal influenza vaccine this past June, and expects top-line results soon, it said in a release. It’s made up of four strains of the virus that are each fused to a flagellin protein, w... |
| 03.10.2014 | Well-capitalized VaxInnate gets another $6M for its bacteria-based flu vaccines | Vaxinnate claims it’s got the ability to do rapid-response manufacturing, generating 50 million doses within 5-6 months, it said, with the first doses available at the three month mark – making it able to meet a pandemic head-on. The compan... |
| 02.04.2012 | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | Last year, it was granted a five-year research grant valued up to $196 million by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to fund the development of seasonal and ... |
| 26.07.2007 | VaxInnate wins $597K grant for Dengue-fever vaccine | VaxInnate, a Cranbury, N.J., vaccine-focused biotech, received a $597,000 small-business innovation grant from the NIH to support work on a vaccine against Dengue fever, a mosquito-borne viral disease. VaxInnate’s primary focus is on new in... |
| 25.10.2006 | Vaccine co., VaxInnate, raises $40 from Canaan & others | VaxInnate, of Cranbury, NJ said it has raised $40 million in a Series C financing for its development of vaccines for pandemic and seasonal influenza. It is the latest in a series of investments in the sector, as concern rises about the ris... |
| - | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | The former head of Sanofi’s (NYSE:SNY) vaccines division, one of the largest vaccine companies in the world, has joined a biotechnology company developing infectious disease vaccines as its CEO. Wayne Pisano will lead Cranbury, New Jersey-b... |
| - | VaxInnate keeps slowly raising capital for seasonal flu vaccine | New Jersey startup VaxInnate keeps slowly raising capital as it moves forward in clinical trials for a new flu vaccine. The company has raised $3.3 million of a proposed $4.3 million equity round, according to an SEC filing. On top of that,... |
| - | Well-capitalized VaxInnate gets another $6M for its bacteria-based flu vaccines | New Jersey’s VaxInnate is developing inoculations to ward off seasonal and pandemic flu, dengue fever and Clostridium difficile. The well-capitalized company has raised a recent round of $6 million, according to a regulatory filing. The com... |